Mustang Bio's lentiviral gene therapy MB-107 gained the FDA's Regenerative Medicine Advanced Therapy designation as a treatment for X-linked severe combined immunodeficiency, commonly known as bubble boy disease. Mustang Bio and St. Jude Children's Research Hospital are co-developing the therapy.
FDA grants RMAT status to Mustang's bubble boy disease gene therapy
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.